We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.28B
AUM Growth
-$1.41B
Cap. Flow
-$1.19B
Cap. Flow %
-22.61%
Top 10 Hldgs %
53.54%
Holding
466
New
23
Increased
24
Reduced
24
Closed
360

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$72.5M
2
LEGN icon
Legend Biotech
LEGN
+$64.3M
3
OSCR icon
Oscar Health
OSCR
+$64.1M
4
DVAX
Dynavax Technologies
DVAX
+$62.6M
5
INDV icon
Indivior Pharmaceuticals
INDV
+$39M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$187M
2
KURA icon
Kura Oncology
KURA
+$106M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$66.5M
4
SGRY icon
Surgery Partners
SGRY
+$57.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$56.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Industrials 0.23%
3 Consumer Staples 0.01%
4 Energy 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMPL icon
126
Amplitude
AMPL
$1.14B
– –
-127,474
Closed -$1.14M
AMR icon
127
Alpha Metallurgical Resources
AMR
$1.86B
– –
-2,319
Closed -$548K
AMSF icon
128
AMERISAFE
AMSF
$575M
– –
-8,283
Closed -$400K
ANDE icon
129
Andersons Inc
ANDE
$2.55B
– –
-28,632
Closed -$1.44M
AQST icon
130
Aquestive Therapeutics
AQST
$465M
– –
-155,145
Closed -$773K
ARCB icon
131
ArcBest
ARCB
$3.3B
– –
-10,614
Closed -$1.15M
ARDX icon
132
Ardelyx
ARDX
$1.25B
– –
-30,354
Closed -$209K
ARWR icon
133
Arrowhead Research
ARWR
$12B
– –
-26,439
Closed -$512K
EFOR
134
Everforth Inc
EFOR
$936M
– –
-2,911
Closed -$271K
ATXS
135
DELISTED
Astria Therapeutics
ATXS
– –
-12,153
Closed -$134K
AUTL
136
Autolus Therapeutics
AUTL
$381M
– –
-3,639,000
Closed -$13.2M
AVGO icon
137
Broadcom
AVGO
$1.78T
– –
-1,676
Closed -$289K
JBIO
138
Jade Biosciences
JBIO
$1.17B
– –
-40,332
Closed -$2.95M
AVXL icon
139
Anavex Life Sciences
AVXL
$232M
– –
-105,484
Closed -$599K
BA icon
140
Boeing
BA
$173B
– –
-3,123
Closed -$475K
BANC icon
141
Banc of California
BANC
$3.22B
– –
-65,140
Closed -$960K
BBDC icon
142
Barings BDC
BBDC
$873M
– –
-102,058
Closed -$1M
BDX icon
143
Becton Dickinson
BDX
$46.3B
– –
-6,312
Closed -$1.52M
BFAM icon
144
Bright Horizons
BFAM
$4.24B
– –
-3,937
Closed -$552K
BIIB icon
145
Biogen
BIIB
$29.9B
– –
-3,504
Closed -$679K
BL icon
146
BlackLine
BL
$1.85B
– –
-11,079
Closed -$611K
BMRN icon
147
BioMarin Pharmaceuticals
BMRN
$12.1B
– –
-9,255
Closed -$651K
BNTX icon
148
BioNTech
BNTX
$23.1B
– –
-174,500
Closed -$20.7M
BRBR icon
149
BellRing Brands
BRBR
$1.6B
– –
-11,235
Closed -$682K
BROS icon
150
Dutch Bros
BROS
$8.88B
– –
-18,742
Closed -$600K
4 5
6
7 8

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2024 Portfolio in Review

As of Q4 2024, Deerfield Management held 466 positions worth $5.28B, down 21% from $6.69B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $1.19B in Q4 2024, closing 360 positions and reducing 24 holdings. Its most notable exit was Kura Oncology, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Deerfield Management opened a new position in Legend Biotech worth $50.5M.

  • Deerfield Management's largest Q4 2024 buy was Legend Biotech: 1,551,718 shares worth $50.5M.
  • Deerfield Management added most to NewAmsterdam Pharma in Q4 2024, an estimated $72.5M increase.
  • Deerfield Management's biggest Q4 2024 reduction was Nuvalent, cutting an estimated $187M.
  • Deerfield Management fully exited Kura Oncology in Q4 2024, selling an estimated $106M.
  • Deerfield Management's ten largest holdings make up 54% of its $5.28B portfolio in Q4 2024.
  • Deerfield Management opened 23 new positions and closed 360 in Q4 2024.
  • Deerfield Management's portfolio value fell 21% quarter-over-quarter to $5.28B.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.